Phil Blog

Phil Blog

Why Strong Market Access Doesn’t Always Translate to Covered Dispenses

Strong market access, the ability of a pharmaceutical manufacturer to secure reimbursement and coverage for their products from payers and other decision-makers, does not always translate to covered dispenses at the pharmacy level – particularly for specialty and specialty-lite therapies. Manufacturers must also navigate a complex prescription fulfillment and payer utilization management landscape to overcome barriers to patient access. Here are the three biggest reasons why good market access does not guarantee coverage and what commercialization teams can do to overcome this challenge

Tech Enabled Patient Services: Do More With Less in 2023

More recently though, as life science companies strive to ensure improved access to their therapies and reduce operational costs, they are turning to disruptive technology platforms that offer the potential to break through barriers to medication. Unfortunately, some companies are still wrapped up in the old paradigm and spend millions of dollars on patient access solutions but get little in return. Here are four ways a technology-driven patient services solution can enable life science companies to achieve more in 2023: Automating workflows From the point of prescribing to driving therapy adherence, automated processes reduce friction across the patient’s medication journey

Duchesnay USA’s Women’s Healthcare Launches on Phil

SAN FRANCISCO--(BUSINESS WIRE)--Today, Phil Inc., a patient access platform company that revolutionizes life science product commercialization, announced that Duchesnay USA’s Bonjesta® (doxylamine succinate and pyridoxine hydrochloride), a prescription medicine used to treat nausea and vomiting of pregnancy in women who have not improved with change in diet or other non-medicine treatments, is now available to be prescribed via its patient access platform. It is not known if Bonjesta® is safe and effective in women with severe nausea and vomiting of pregnancy, a condition called hyperemesis gravidarum. The most common side effect of Bonjesta® is drowsiness.Phil’s customizable platform helps patients receive and refill medicines quickly, easily and affordably while giving life science companies unprecedented end-to-end visibility into the prescription life cycle

Policy Updates Drug Manufacturers Need to Know

The pharmaceutical industry is one of the most highly regulated industries in the United States. Despite many legal and regulatory obstacles, the U.S. has led the world in the number of new chemical and biological entity launches since the year 2000

Metrics that matter when measuring your access program

For life science companies, patient support services have become as vital to a brand’s success as efficacy and price. A patient support services program has the potential to help break through barriers to medication access. That’s why it’s crucial to make sure it aligns with your business goals and delivers on your brand objectives while helping patients access their therapy as easily as possible